| Enrolled Patients N (%) | |||
All patients N = 34 | BSG - 11 | HG - 13 | LG - 10 | |
Characteristic |
|
|
|
|
Age median | 10.4 years | 2.9 years | 3.8 years | 5.9 years |
Age range | 0.8 - 17.8 years | 2.7 - 12.25 years | 3.3 - 17.8 years | 0.8 - 17.3 years |
Male | 13 (35%) | 1 | 8 | 4 |
Female | 21 (65%) | 10 | 5 | 6 |
Ethnicity | W 32 (94%), B 1 (3%), M 1 (3%) | W (100%) | W 12 (92%), B 1 (8%) | W 9 (90%), M 1 (10%) |
Median Karnofsky Performance Score | 80 baseline/80 last evaluation | 80 baseline/80 last evaluation | 80 baseline/70 last evaluation | 90 baseline/90 last evaluation |
Tumor Histology |
|
|
|
|
DIPG | 9 | 9 |
|
|
BSG/midbrain (pilocytic astrocytoma) | 2 | 2 |
|
|
GBM | 5 |
| 5 |
|
Anaplastic oligodendroglioma | 1 |
| 1 |
|
Gliosarcoma | 1 |
| 1 |
|
Anaplastic astrocytoma | 3 |
| 3 |
|
Anaplastic glioma | 1 |
| 1 |
|
sPNET (medulloepithelioma) | 1 |
| 1 |
|
PNET (medulloblastoma) | 1 |
| 1 |
|
Astrocytoma | 2 |
|
| 2 |
Pilocytic astrocytoma | 1 |
|
| 1 |
Craniopharyngioma | 1 |
|
| 1 |
Ganglioglioma | 2 |
|
| 2 |
Ganglioma-desmoplastic infantile | 1 |
|
| 1 |
Neurocytoma | 1 |
|
| 1 |
Oligodendroglioma | 1 |
|
| 1 |
Optic pathway | 1 |
|
| 1 |
Prior treatment |
|
|
|
|
None or biopsy only | 6 | 2 | 2 | 2 |
SU | 16 | 1 | 8 | 7 |
SU + CH + RT | 3 | 0 | 3 | 0 |
CH | 2 | 1 | 0 | 1 |
CH + RT | 3 | 3 | 0 | 0 |
RT | 4 | 4 | 0 | 0 |
SU + RT | 0 | 0 | 0 | 0 |